In detail, D’Eufemia et al. reported that CK-BB levels time-dependently increased in OI patients treated with neridronate, whereas its levels were slightly but not significantly elevated with respect to the controls before starting treatment [12]. This evidence concerns the gene CKB and osteogenesis imperfecta.